BPC-157: what the evidence in people actually shows

BPC-157 has been studied in people exactly three times in the published literature, in a combined 30 or so patients, and none of those studies had a control group. Everything else, including the tendon, gut and nerve results you see quoted, comes from rats, mice and cells. That doesn't make it useless; it makes it unproven, and the gap between those two words is the subject of this guide.

What it is

BPC-157 is a chain of 15 amino acids (GEPPPGKPADDAGLV) described by its original researchers as a stable fragment of a protein found in human gastric juice [7]. Most of the work on it comes from one group at the University of Zagreb, which has published on it since the early 1990s. The Croatian drug company Pliva developed it as a medicine for inflammatory bowel disease under the codes PL 14736 and PLD-116 [6].

None of the papers we reviewed identifies a specific receptor for BPC-157, so what follows is mechanism theory, not settled biology. The most cited idea is that it encourages new blood vessels to grow into injured tissue. A Taiwanese lab outside the Zagreb group found that it increased levels of the VEGFR2 receptor on human endothelial cells in culture and switched on the Akt–eNOS signalling chain; in rats it sped the return of blood flow to an ischaemic hind limb [9]. Reviews also describe effects on nitric oxide signalling, growth hormone receptor expression in tendon cells, and cell migration [1,5]. All of this was measured in cells or rodents.

The human evidence

A 2025 systematic review searched every database up to June 2024 for BPC-157 in musculoskeletal injury. It found 544 records and kept 36 studies: 35 preclinical and one clinical [1]. A later narrative review counted three human pilot studies across all uses [5]. Here they are.

Knee pain: a phone survey of 16 patients

A clinic in Orlando reviewed charts from 2019 to 2020 and phoned patients who'd had BPC-157 injected into the knee, alone or with thymosin beta-4, six months to a year earlier [2]. Sixteen were reached. Of the 12 given BPC-157 alone, 11 said their pain improved significantly. The authors used no standard pain or function scale, took no scans, and had no comparison group, and the knee problems ranged from osteoarthritis to ligament tears. The 2025 systematic review summarised the same paper as 7 of 12 patients reporting relief lasting more than six months [1], which tells you how soft the underlying numbers are.

Interstitial cystitis: 12 women, one injection

The second study treated 12 women with interstitial cystitis (bladder pain syndrome) who had not responded to pentosan polysulfate [3]. During a single cystoscopy, doctors injected 10 mg of BPC-157 from a US compounding pharmacy around the inflamed area of the bladder. Ten of 12 reported complete resolution of symptoms and the other two about 80% improvement, with no adverse events. That's a striking result for a condition that is often stubborn. It's also a single-arm study with a self-rated outcome and no placebo, in a disease where placebo responses are common, so it can't separate the peptide from the procedure or from expectation.

Intravenous safety: two people

The 2025 IV pilot, by Lee and Burgess, infused BPC-157 into two adults at a private clinic in Florida: 10 mg over an hour on day one and 20 mg on day two [4]. Both had received IV BPC-157 before. Blood tests covering the heart, liver, kidneys, thyroid and glucose didn't change, and neither reported side effects. The authors call this evidence of safety in humans. Two people over three days can show that a dose didn't cause an obvious acute problem in those two people; it can't say anything about rare, delayed or long-term effects.

All three papers share a first author, came from private practice rather than a university trial unit, and appeared in the same journal. That's worth knowing, though not a reason to dismiss them.

The colitis trial that never reported

The most important human study of BPC-157 may be one nobody can read. As PL 14736, it went into Phase II trials for inflammatory bowel disease in the early 2000s [6]. The Zagreb group wrote in 2012 that it had been tested "so far only" in Phase II for IBD and described it as free of side effects in those trials [7]. We couldn't find a full, peer-reviewed report of the ulcerative colitis results, or a registry entry with posted outcomes. Development stopped without a public explanation. A separate Phase 1 trial of an oral tablet (PCO-02) registered 42 healthy volunteers in 2015; its status is listed as unknown and no results are posted [12]. Until those data appear, the claim that BPC-157 "passed" human trials in colitis rests on the developers' own summary.

What is running now

The first properly designed trial for a sports injury is under way. A US company registered a randomised, double-blind, placebo-controlled Phase 2 trial in 120 people with MRI-confirmed grade II hamstring strains, comparing 14 days of daily injections with placebo on top of standard rehab [11]. Its primary outcomes are days to return to sport and change in injury volume on MRI. The estimated completion date is 2028.

What the animal and lab work suggests

The rodent literature is large and consistently positive. In rats with a cut Achilles tendon, daily BPC-157 improved load to failure, stiffness, walking function and the look of the healing tissue over 14 days [6]. Similar results exist for ligament, muscle and bone in rats [1]. A 2019 review of the soft-tissue work noted that every study it found reported a benefit, and that almost all were done in small rodents [10]. A literature with no negative results tends to mean unpublished null findings or a narrow set of labs, not a perfect drug.

Pharmacokinetics are known only in animals. In rats and dogs, BPC-157 had an elimination half-life under 30 minutes and was quickly broken down into small fragments and single amino acids; absolute bioavailability after an intramuscular injection was about 14–19% in rats and 45–51% in dogs [8]. There are no published human pharmacokinetic data.

Safety and side effects reported

The three human reports describe no adverse events in about 30 people [2,3,4]. That is far too few to detect anything but common, immediate effects. The Zagreb group reports that animal toxicology found no toxic effect and never reached a lethal dose [7]; that is the developers’ own account.

Two concerns come up repeatedly in reviews. The first is theoretical: a compound that encourages blood vessel growth could, in principle, help an existing tumour grow its own supply, and no study has tested this [5]. The second is practical. Almost all BPC-157 used outside trials comes from unregulated sources, and the 2025 systematic review flags contamination and inconsistent manufacturing as real risks independent of the peptide itself [1]. FDA staff raised immunogenicity and adverse event reports in the US FDA Adverse Event Reporting System in their July 2026 briefing, according to one law-firm summary [14].

Legal and regulatory status

United States. BPC-157 isn't an FDA-approved drug. On 23 July 2026, the FDA's Pharmacy Compounding Advisory Committee considered whether pharmacies may compound it (the nominated use was ulcerative colitis) [13]. The committee voted 8 to 6, with one abstention, to recommend adding it to the list of substances that 503A pharmacies can use, against the FDA's own briefing, which proposed not adding it and cited thin human evidence [14]. The vote is advisory. The FDA says its committees make non-binding recommendations [13], and any change would need formal rulemaking.

United Kingdom. It isn't a licensed medicine in the UK, and no UK regulator has assessed it for any use.

Sport. WADA names BPC-157 as an example under S0, non-approved substances, prohibited at all times in and out of competition [15].

What we still don’t know

• Whether BPC-157 does anything in people that a placebo injection doesn't. No completed placebo-controlled trial has been published.
• What happened in the PL 14736 colitis trials, and why development stopped.
• How it behaves in the human body: absorption, half-life and whether oral dosing reaches the blood.
• Long-term safety, including any effect on existing cancers, which has never been studied.
• Whether the hamstring trial [11] will report on time, and what it will show.

Educational content only — not medical advice. Many peptides discussed on HPR are not approved for human use. Talk to a qualified clinician before making any decision about your health.